Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NBE5
- Development stage
- Unknown
- Lead developer
- Shandong University
- Modality
- PROTACs (E3 ligase recruitment) → Targeted Protein Degraders (TPDs) → Small Molecules, Bivalent/Multivalent Binders → Multivalent & Scaffold-Based Small Molecules → Small Molecules
01
Overview
NBE5: sourced facts only. name: "NBE5 effectively degraded Keap1 and activated the Nrf2 antioxidant response." [PMID:41722428]; target: "NBE5 effectively degraded Keap1 and activated the Nrf2 antioxidant response." [PMID:41722428]; developer: "Key Laboratory of Chemical Biology (Ministry of Education), School of Pharmaceutical Sciences, Cheeloo College of Medicine, Shandong University, Jinan, 250012, PR China." [PMID:41722428]; modality: "leading to the identification of NBE5, a norbornene-tag-containing degrader, as the most potent compound." [PMID:41722428]
02
Targets
KEAP1 (Kelch-like ECH-associated protein 1)
Beyond the preview
Go deeper on NBE5.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NBE5.